Solventum’s (SOLV) Buy Rating Reaffirmed at BTIG Research

Posted by Francis Steltz on May 6th, 2026

Solventum (NYSE:SOLV – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a report released on Wednesday,Benzinga reports. They currently have a $89.00 price objective on the stock. BTIG Research’s price objective indicates a potential upside of 28.82% from the stock’s previous close.

SOLV has been the subject of several other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Piper Sandler cut their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Mizuho set a $100.00 target price on shares of Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Wells Fargo & Company raised shares of Solventum to a “hold” rating in a report on Wednesday, March 18th. Finally, Stifel Nicolaus lifted their target price on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $88.45.

Check Out Our Latest Stock Report on SOLV

Solventum Stock Performance

SOLV opened at $69.09 on Wednesday. Solventum has a 12-month low of $62.38 and a 12-month high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $11.98 billion, a PE ratio of 7.79, a P/E/G ratio of 1.10 and a beta of 0.59. The firm has a 50 day moving average of $67.91 and a two-hundred day moving average of $74.51.

Solventum (NYSE:SOLV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the firm posted $1.34 EPS. Solventum’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts anticipate that Solventum will post 6.5 EPS for the current year.

Insider Buying and Selling at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director directly owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.24% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Solventum

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its holdings in Solventum by 14.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,632 shares of the company’s stock worth $427,000 after acquiring an additional 827 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Solventum by 22.1% in the 1st quarter. Sanctuary Advisors LLC now owns 32,664 shares of the company’s stock worth $2,133,000 after acquiring an additional 5,915 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Solventum by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 167,833 shares of the company’s stock worth $10,959,000 after acquiring an additional 5,145 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in Solventum by 29.3% in the 1st quarter. Diversify Wealth Management LLC now owns 4,694 shares of the company’s stock worth $312,000 after acquiring an additional 1,065 shares in the last quarter. Finally, General American Investors Co. Inc. increased its holdings in Solventum by 6.4% in the 1st quarter. General American Investors Co. Inc. now owns 377,350 shares of the company’s stock worth $24,641,000 after acquiring an additional 22,700 shares in the last quarter.

Key Stories Impacting Solventum

Here are the key news stories impacting Solventum this week:

Positive Sentiment: Q1 beat on both profit and sales — reported EPS $1.48 vs. consensus $1.35 and revenue $2.01B vs. $1.97B — underpinning investor optimism. Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
Positive Sentiment: Management guided FY2026 EPS to 6.600 (top of prior range), slightly above consensus, citing stronger wound-care and sterilization product demand — a concrete forward catalyst. Solventum forecasts annual profit at higher end on wound care demand
Positive Sentiment: Earnings call highlighted margin momentum and operational improvements that could lift profitability going forward. Solventum Earnings Call Signals Margin Momentum Ahead
Neutral Sentiment: Organic sales grew 2.1% and the company reaffirmed organic sales and free cash flow guidance, even as reported sales fell 3.0% (FX/divestiture effects cited). Solventum Reports First Quarter 2026 Financial Results
Neutral Sentiment: Key profitability metrics remain strong (net margin ~18.7%, ROE ~25%), and valuation looks inexpensive on a P/E ~7.8 — but these are context-dependent for investors deciding between value vs. growth exposure.
Negative Sentiment: Reported revenue was down 3% year-over-year, suggesting pockets of softness; some analysts remain cautious with a consensus “Hold” and outside commentary flagged macro/AI-related execution risks that could test the turnaround story. Solventum earnings up next as AI concerns test turnaround story

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.